LIQUID BIOPSY

 

 

Liquid biopsy presents an amazing chance to transform our health care from a reactive to a proactive system. With the help of AI and advanced analytics systems we are now able to perform non-invasive liquid biopsy procedures for regular monitoring of vulnerable patients whilst altering treatment pathways in real time to provide a more personalised approach to therapy reducing suffering and costs.

THIS YEAR’S WORLD LEADING LIQUID BIOPSY SPEAKERS

 

 

 

Liquid Biopsy, Tuesday 2 November 2021

08:40

Opening Remarks

Trevor Howe
09:00

Looking at the bigger picture: How do we make sure that we have the full picture with big data experiments

Joachim Reischl
09:20

Deep Medicine – towards the next generation of software-based precision medicine diagnostics

  • Evolution of precision medicine
  • AI in predicting clinical outcome
  • Software as Medical Device as Companion Diagnostic
Panel discussion
09:40

Essential Tools for Accelerating Pipeline Productivity & Success

What tools are in your toolkit? Join this leading biopharma panel discussion to find out how to give your AI-based drug discovery and development program a competitive edge and increase program success.
10:40

Networking Break

Liquid Biopsy
12:00

ThermoFisher

Liquid Biopsy
12:40

Beckman Coulter Life Science

Bernhard Polzer
Liquid Biopsy
13:00

Clinical applications for the analysis of rare single cells

  • Detection, isolation and analysis of rare cells from patient samples
  • Transfering the liquid biopsy concept from blood to other organs (e.g. CSF or lymph nodes)
  • Molecular characterization of single tumor cells from CSF of patients with primary and secondary brain cancers
  • Early colonization of lymph nodes in melanoma patients
13:20

Networking Lunch Break

Liquid Biopsy
15:00

10X Genomics

Liquid Biopsy
15:40

Bio-techne

Catherine Alix Panabieres
Liquid Biopsy
16:00

Circulating Tumor Cells as Liquid Biopsy: From Discovery to Clinical Application

  • How to detect and analyze single viable CTCs?
  • Clinical relevance of CTCs: the example of PD-L1 in Onco-immunology
  • Challenges to establish CTC lines from metastasis-competent CTCs in colon cancer
16:20

Networking Break

Liquid Biopsy
17:00

INTERVENN

Liquid Biopsy
17:20

Omega Biotech

Liquid Biopsy
17:40

illumina

18:00

Neri & Sons Band & Networking Drinks Reception

last published: 27/Jul/21 14:25

Liquid Biopsy, Wednesday 3 November 2021

Steffen Roellinger
09:00

Decentralised Clinical Trials

  • Discussing the adoption of decentralised clinical trials at Bayer
  • New digital addoption
  • The Bayer trials transformaiton over COVID-19
Andrew Kasarskis
09:00

Digital transformation over COVID-19 – Challenges for the future and perpetuating the efforts

  • COVID-19 lead to digital innovation by necessity, including telehealth, new apps and digital technologies, and data fusion and sharing advances.
  • Large opportunities exist to do much better with learning from data, however.This requires the following operational and cultural change:
-Proactive collection and use of coherent data sets as a baseline for public health and the infrastructure development to support that work.-Recommitment to evidence-based medicine and timely, rigorous assessment of clinical utility through ongoing clinical research with well-powered studies of strong statistical design coupled to careful monitoring of large observational data.
Said Ismail
09:20

Qatar Genome; Big data from an underrepresented region

  • Overview of the Qatar Genome Project (QGP)
  • Contributions to Middle East Genomics
  • QGP role COVID-19 research
  • Strategy for precision medicine implementation
09:20

SevenBridges

Panel discussion
09:40

BC Platforms - Keynote Panel

Paul Agapow
09:40

How to be right: effective use of clinical models and machine learning in the clinic

    There is an increasing demand for a sophisticated model to predict patient outcomes and suggest treatmentsUnfortunately, most proposed clinical models are not fit for purpose, being biased, unvalidated, or irrelevantHere we suggest best practices for the development and deployment of complex ML algorithms, resulting in more successful and effective models
10:20

Networking Break + Speed Networking

13:00

Networking Lunch Break

16:00

Networking Break

18:00

Drinks Reception

last published: 27/Jul/21 14:25

Liquid Biopsy, Thursday 4 November 2021

Scott Chandler
09:00

Genetic Drivers of Response to Immunotherapy: Going Beyond the Tumor

09:20

GenomeSys

Thomas Hach
10:40

The Future of Precision Healthcare – Multi-Omics Humanized

  • Personalization of healthcare, not only of drug treatment, is the future
  • Patient influence, patient data and patient-desired outcomes are the most disruptive factors
  • How can we move from sterile biosignatures to a humanized approach?
last published: 27/Jul/21 14:26

GET INVOLVED AT BIODATA WORLD CONGRESS

 

 

TO SPONSOR


Alistair Wilmot
alistair.wilmot@terrapinn.com
0207 092 1174

 

 

TO SPEAK


Edward Glanville

edward.glanville@terrapinn.com
0207 092 1042

 

 

MARKETING OPPORTUNITIES


Onika Akhtar
onika.akhtar@terrapinn.com
0207 092 1034